Loading organizations...
§ Private Profile · Sioux Falls, SD, USA
Biopharmaceutical company developing large-scale antibody therapeutics.
SAB Biotherapeutics has raised $37.4M across 3 funding rounds.
SAB Biotherapeutics has raised $37.4M in total across 3 funding rounds.
SAB Biotherapeutics has raised $37.4M in total across 3 funding rounds.
SAB Biotherapeutics's investors include Merck, South Dakota Equity Partners, National Institutes of Health.
SAB Biotherapeutics has raised $37.4M across 3 funding rounds. Most recently, it raised $14.0M Series B in July 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 17, 2020 | $14M Series B | — | Merck, South Dakota Equity Partners | Announced |
| Dec 20, 2018 | $22M Series A | — | — | Announced |
| Sep 9, 2016 | $1.4M Grant | National Institutes OF Health | — | Announced |